Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • The CAPACITY-COVID Collaborative Consortium and LEOSS Study Group - (Author)
  • Clinical Infectious Disease Unit
  • Utrecht University
  • University College London
  • The Dutch Network for Cardiovascular Research (WCN)
  • University of Cologne
  • German Center for Infection Research, Partner Site Bonn-Cologne
  • University College London Hospitals NHS Foundation Trust
  • Interuniversity Cardiology Institute of the Netherlands
  • Amphia Hospital
  • Erasmus University Rotterdam
  • Maasstad Hospital
  • Northumbria Healthcare NHS Trust
  • Leiden University
  • Barts Health NHS Trust
  • University Hospital Frankfurt
  • University of Groningen
  • Martini Ziekenhuis
  • Imam Abdulrahman Bin Faisal University
  • Gelre Ziekenhuizen
  • Newcastle University
  • University of Exeter
  • Treant Zorggroep
  • Deventer Ziekenhuis
  • St. Jansdal Hospital
  • St. Antonius Hospital
  • Ludwig Maximilian University of Munich
  • German Cancer Research Center (DKFZ)
  • Bavarian Center for Cancer Research (BZKF)
  • Azienda Ospedaliera S. Luigi Gonzaga
  • Sechenov First Moscow State Medical University
  • University of Amsterdam
  • Ingolstadt Hospital
  • Bravis Hospital
  • Medical Centre Leeuwarden
  • University Hospital Carl Gustav Carus Dresden

Abstract

Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality. Methods and results We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existing heart disease and in-hospital mortality. A total of 16 511 patients with COVID-19 were included (21.1% aged 66-75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male, and often had other comorbid conditions when compared with those without. Mortality was higher in patients with cardiac disease (29.7%; n = 1545 vs. 15.9%; n = 1797). However, following multivariable adjustment, this difference was not significant [adjusted risk ratio (aRR) 1.08, 95% confidence interval (CI) 1.02-1.15; P = 0.12 (corrected for multiple testing)]. Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for heart failure (aRR 1.19, 95% CI 1.10-1.30; P < 0.018) particularly for severe (New York Heart Association class III/IV) heart failure (aRR 1.41, 95% CI 1.20-1.64; P < 0.018). None of the other heart disease subtypes, including ischaemic heart disease, remained significant after multivariable adjustment. Serious cardiac complications were diagnosed in <1% of patients. Conclusion Considerable heterogeneity exists in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with heart failure are at greatest risk of death when hospitalized with COVID-19. Serious cardiac complications are rare during hospitalization.

Details

Original languageEnglish
Pages (from-to)1104-1120
Number of pages17
JournalEuropean heart journal
Volume43
Issue number11
Publication statusPublished - 2022
Peer-reviewedYes

External IDs

PubMed 34734634
ORCID /0000-0001-9473-3018/work/148606196

Keywords

Sustainable Development Goals

Keywords

  • Cardiovascular disease, Comorbidity, COVID-19, Epidemiology, Patient registry, SARS-CoV-2